Compare ALEMBIC with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs GLENMARK PHARMA - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC GLENMARK PHARMA ALEMBIC/
GLENMARK PHARMA
 
P/E (TTM) x 57.8 15.2 380.9% View Chart
P/BV x 5.0 2.5 200.0% View Chart
Dividend Yield % 0.2 0.4 50.7%  

Financials

 ALEMBIC   GLENMARK PHARMA
EQUITY SHARE DATA
    ALEMBIC
Mar-18
GLENMARK PHARMA
Mar-19
ALEMBIC/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs72712 10.1%   
Low Rs34484 7.0%   
Sales per share (Unadj.) Rs4.7349.6 1.3%  
Earnings per share (Unadj.) Rs6.132.8 18.6%  
Cash flow per share (Unadj.) Rs6.244.3 14.1%  
Dividends per share (Unadj.) Rs0.202.00 10.0%  
Dividend yield (eoy) %0.40.3 112.9%  
Book value per share (Unadj.) Rs40.7198.6 20.5%  
Shares outstanding (eoy) m267.03282.17 94.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.31.7 659.0%   
Avg P/E ratio x8.718.2 47.6%  
P/CF ratio (eoy) x8.513.5 62.9%  
Price / Book Value ratio x1.33.0 43.3%  
Dividend payout %3.36.1 53.7%   
Avg Mkt Cap Rs m14,139168,625 8.4%   
No. of employees `000NA12.0 0.0%   
Total wages/salary Rs m20720,561 1.0%   
Avg. sales/employee Rs ThNM8,196.0-  
Avg. wages/employee Rs ThNM1,708.1-  
Avg. net profit/employee Rs ThNM768.5-  
INCOME DATA
Net Sales Rs m1,25598,655 1.3%  
Other income Rs m3702,081 17.8%   
Total revenues Rs m1,625100,736 1.6%   
Gross profit Rs m11115,858 0.7%  
Depreciation Rs m383,259 1.2%   
Interest Rs m23,346 0.1%   
Profit before tax Rs m44211,335 3.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m243,756 0.6%   
Profit after tax Rs m1,6309,250 17.6%  
Gross profit margin %8.916.1 55.1%  
Effective tax rate %5.433.1 16.4%   
Net profit margin %129.89.4 1,384.9%  
BALANCE SHEET DATA
Current assets Rs m1,86766,968 2.8%   
Current liabilities Rs m59140,211 1.5%   
Net working cap to sales %101.627.1 374.8%  
Current ratio x3.21.7 189.6%  
Inventory Days Days9483 113.1%  
Debtors Days Days7481 90.6%  
Net fixed assets Rs m1,79133,322 5.4%   
Share capital Rs m534282 189.3%   
"Free" reserves Rs m10,32455,770 18.5%   
Net worth Rs m10,85856,052 19.4%   
Long term debt Rs m4135,738 0.1%   
Total assets Rs m11,591132,888 8.7%  
Interest coverage x260.94.4 5,945.9%   
Debt to equity ratio x00.6 0.6%  
Sales to assets ratio x0.10.7 14.6%   
Return on assets %14.19.5 148.5%  
Return on equity %15.016.5 91.0%  
Return on capital %15.217.8 85.3%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1962,998 0.0%   
Fx outflow Rs m26422,859 1.2%   
Net fx Rs m-24440,140 -0.6%   
CASH FLOW
From Operations Rs m23613,242 1.8%  
From Investments Rs m-224-6,990 3.2%  
From Financial Activity Rs m-27-7,387 0.4%  
Net Cashflow Rs m-15-2,971 0.5%  

Share Holding

Indian Promoters % 64.0 48.3 132.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 6.9 2.9%  
FIIs % 9.7 34.4 28.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 10.5 248.6%  
Shareholders   54,701 56,727 96.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT  GSK PHARMA  PANACEA BIOTECH  

Compare ALEMBIC With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Plunges 746 Points; Banking & Metal Stocks Bleed(Closing)

Indian share markets witnessed huge selling pressure today and extended losses as the session progressed, dragged down by heavy selling in metal and banking stocks.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


Jan 22, 2021 (Close)

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE ALEMBIC WITH

MARKET STATS